Gilead Sciences (GILD) — insider trading
Health Care
Gilead Sciences (GILD) has 27 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 27 (latest 2026-07-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Open-market sale | 3,000 | $129.92 | $389.8K | Form 4 |
| 2026-07-15 | Dickinson Andrew D | Officer (Chief Financial Officer) | Open-market sale | 3,000 | $129.93 | $389.8K | Form 4 |
| 2026-07-01 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Open-market sale | 3,100 | $127.08 | $393.9K | Form 4 |
| 2026-07-01 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Open-market sale | 11,900 | $126.09 | $1.50M | Form 4 |
| 2026-06-15 | Dickinson Andrew D | Officer (Chief Financial Officer) | Open-market sale | 3,000 | $125.40 | $376.2K | Form 4 |
| 2026-06-15 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Open-market sale | 450 | $125.40 | $56.4K | Form 4 |
| 2026-06-15 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Open-market sale | 1,070 | $124.00 | $132.7K | Form 4 |
| 2026-06-15 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Open-market sale | 1,480 | $123.42 | $182.7K | Form 4 |
| 2026-06-10 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Option exercise / conversion (derivative) | 8,779 | — | — | Form 4 |
| 2026-06-10 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Shares withheld for taxes / exercise cost | 4,213 | $121.48 | $511.8K | Form 4 |
| 2026-06-10 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Option exercise / conversion | 8,779 | — | — | Form 4 |
| 2026-06-10 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Option exercise / conversion (derivative) | 2,796 | — | — | Form 4 |
| 2026-06-10 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Shares withheld for taxes / exercise cost | 1,341 | $121.48 | $162.9K | Form 4 |
| 2026-06-10 | Mercier Johanna | Officer (Chief Comm & Corp Aff Officer) | Option exercise / conversion | 2,796 | — | — | Form 4 |
| 2026-06-10 | Dickinson Andrew D | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,796 | — | — | Form 4 |
| 2026-06-10 | Dickinson Andrew D | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 1,341 | $121.48 | $162.9K | Form 4 |
| 2026-06-10 | Dickinson Andrew D | Officer (Chief Financial Officer) | Option exercise / conversion | 2,796 | — | — | Form 4 |
| 2026-06-10 | Cain Wettan Keeley M | Officer (EVP Gen Counsel, Legal & Comp) | Option exercise / conversion (derivative) | 589 | — | — | Form 4 |
| 2026-06-10 | Cain Wettan Keeley M | Officer (EVP Gen Counsel, Legal & Comp) | Shares withheld for taxes / exercise cost | 283 | $121.48 | $34.4K | Form 4 |
| 2026-06-10 | Cain Wettan Keeley M | Officer (EVP Gen Counsel, Legal & Comp) | Option exercise / conversion | 589 | — | — | Form 4 |
| 2026-06-10 | Berger Dietmar | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 533 | — | — | Form 4 |
| 2026-06-10 | Berger Dietmar | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 263 | $121.48 | $31.9K | Form 4 |
| 2026-06-10 | Berger Dietmar | Officer (Chief Medical Officer) | Option exercise / conversion | 533 | — | — | Form 4 |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Open-market sale | 1,038 | $132.97 | $138.0K | Form 4 |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Open-market sale | 3,062 | $132.22 | $404.8K | Form 4 |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer (Chairman & CEO) | Open-market sale | 10,900 | $131.10 | $1.43M | Form 4 |
| 2026-05-26 | GILEAD SCIENCES, INC. | 10% owner | Grant / award / vesting | 471,698 | $26.50 | $12.50M | Form 4 |
Ask the chat about GILD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Gilead Sciences (GILD).
Last updated 2026-07-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.